window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical Trials

  • Digital & Data,Drug Discovery & Development

    Medable launches programme to support AI deployment in clinical development

    Medable has launched a new support programme aimed at helping [...]

    June 9, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Veristat launches AI biostatistics platform to accelerate clinical trial data readouts

    Veristat has launched an AI-enabled biostatistics platform designed to reduce [...]

    May 15, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Incannex links PSX-001 psilocybin programme to White House push on psychedelic mental health treatments

    Incannex Healthcare has said its PSX-001 oral synthetic psilocybin programme [...]

    May 14, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Life Biosciences raises $80M to advance gene therapy for optic neuropathies

    Life Biosciences has raised $80m in a Series D financing [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Levicept reports Phase 2 osteoarthritis data in The Lancet showing pain reduction with LEVI-04

    Levicept has reported Phase 2 clinical trial results for LEVI-04 [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events

    Strong scientists: PHARMExcel’s Margaret Irwin on clinical research careers and early stage trials

    From hospital haematology to leading early stage clinical trials, Margaret [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Hemab Therapeutics wins FDA breakthrough therapy status for sutacimig in Glanzmann thrombasthenia

      The FDA has granted breakthrough therapy designation to Hemab [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Evinova and Bristol Myers Squibb collaborate on AI-driven clinical trial optimisation

    Evinova and Bristol Myers Squibb have entered a strategic collaboration [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • $3M funding targets tau-driven neurodegenerative diseases
    Categories: Central Nervous System, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Cancer vaccine research secures $2.5M NIH award for nanoparticle treatment
    Categories: Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Protagonist’s Mimrylo for polycythemia vera, triggering $275M in payments
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top